Olema Oncology To Present Preclinical Data For OP-3136, A Potent KAT6 Inhibitor, Demonstrating Anti-Tumor Activity In Multiple Solid Tumor Models At The 2025 AACR Annual Meeting

Author: Benzinga Newsdesk | March 25, 2025 04:35pm

Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology", NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced it will present a poster highlighting preclinical anti-tumor activity of OP-3136, a novel small molecule that potently and selectively inhibits lysine acetyltransferase 6 (KAT6), in prostate, ovarian, and non-small cell lung cancer models in a late-breaking session at the American Association for Cancer Research (AACR) Annual Meeting taking place April 25-30 in Chicago, Illinois.

Posted In: OLMA